Shi Lichen also said the innovation medicine through negotiations and review the form of a direct access to health insurance directory, drug companies can gain more from innovation medicine research and development and the market in good returns, not only ensure the drug firms r&d's enthusiasm, also can quickly enhance our weak medicine research and development ability, change the present situation of our research is weak.
Based on the above factors, in the consultation stage of the health care directory released by the ministry of social security last year, the popularity of domestic innovative drugs was very high and the inclusion of this was a popular sentiment.
In fact, some places have opened up the gap between innovative drugs and health care. Last year, jiangsu province passed the negotiating mechanism to include five innovative drugs, such as the aylmod tablet, into the health care payment range. It was the best news he had heard in the past year, he said.
Related to drug companies, said publicly, head of innovative medicine into the directory for both the innovation benefit the livelihood of the people, or to promote industry development is crucial, innovative medicine into the medical insurance directory, can satisfy the clinical demand, accelerate the industrialization, encourage corporate innovation.
Entry weight: quality and coverage win
In the "eighth China medical peak BBS", the responsible person believes that the new medicine catalogue will have a bigger impact on hospitals and the industry.
It is understood that in recent ten years in our country medical insurance directory four editions, respectively in 2000 and 2004, 2000 and 2017, species number increased gradually, from 1535 to 1535 of the first, an increase of 1000 kinds.
The above officials believe that the expansion of the health care catalogue is closely related to the expansion of the scope of insurance coverage and the enrichment of insurance types. "2000 medicare catalog is only applicable to urban employee basic medical insurance, at that time, only this one is planted in our country, and now the version is suitable for urban and rural medical insurance, workers' insurance, inductrial injury insurance, birth insurance, serious illness such as health care." He said.
In many MingYiYao industry point of view, in addition to the above changes, the new medical insurance directory is the common disease medicine to the major disease drugs at a lower price, public information, such as tumor and immunity targeted drug treatment were included.
The focus is on why innovative drugs such as Mr Lang can convince the review team to enter the catalogue, where are the competitiveness of these drugs?
The head says health focus more influence include social diseases, the crowd pressing reflect more disease, and children's medicine, medicine conforms to the national policy guidance, such as innovative medicines will be health insurance directory is preferred.
Take lang mu for example, it is the domestic innovation medicine that treats aged sex macular degeneration (AMD). AMD is the leading cause of blindness in older people in industrialized countries. With the comprehensive arrival of the aging society and the direct influence of the blue light on the eyes, the damage degree of the area of the eye has been accelerated. AMD has become the third most blinding eye disease and is listed as one of the fields of global exploration. According to the journal of the American academy of ophthalmology, statistics, each year more than 1 million people live with new to wet macular degeneration, predicts 2020, AMD patients up to 25 million people worldwide, to become the chief culprit of blindness in older people.
According to the data, the prevalence rate of AMD is 1.89% ~ 15.5% in China, while the incidence of brain workers in urban areas is higher. The incidence of the 70-year-old was 11.19 per cent, and the study showed that women were twice as likely to be ill. As the age increases, the risk of the disease significantly increases, with about 300,000 cases of wet age-related macular degeneration in China every year.
Obviously, the market of longmui is in line with the characteristics of the society, the people are eager to reflect more and so on, and it is also in line with the government's policy of encouraging medical innovation and benefiting people's livelihood.
, it seems to the head of the domestic innovation represented by lang mu medicine into the scope of the negotiations and negotiation is successful, the main for the common people, the real beneficiaries "into medicare catalog companies will benefit from this thing is difficult to judge, but since companies willing to reduce the price in the market, it must be" much deliberation.
Through negotiations will have strong social lang mu innovative drugs in drug directory, greatly improve the security level of the basic medical insurance, but also take into account the affordability of funds, and is helpful to guide the reasonable medical behavior, promote the development of medicine industry innovation, health care, business has been basically achieved, ginseng protect people "win-win-win" goals.
A new opportunity for innovative pharmaceutical companies such as kanghong
The change also gives them more ground and support for domestic companies that have been fighting for years on the front lines of new drugs.
It is understood that the development of innovative drugs is difficult in the world. There is a saying in the world of medicine that an innovative drug should go through the "double ten" : it takes 10 years and a billion dollars. High risk, high input, and long periods of investment deter most venture capital and Banks.
For years, the health care policy has not been put in place, leading to the low end of China's pharmaceutical innovation market. The sustainable development of China's pharmaceutical innovation ecosystem shows that in 2015, the market for innovative drugs in the world was almost $600 billion, or about 4 trillion yuan. The world's major pharmaceutical r&d national innovation contribution in the distribution of three tier, China is now in the third tier, contribution to the global pharmaceutical innovation is less than 5%, the market less than $10 billion in total.
In this environment, kanghong pharmaceutical is especially special. What is unique about it is that it has adhered to and fulfilled the idea of "no future without development" since its inception. According to the public information, the proportion of r&d investment in the r&d investment of kanghong pharmaceutical industry is much higher than that of the industry average, and the average of the 2012-2014 average is 5.62%. In 2015, it accounted for 5.57 percent of r&d investment, compared with less than 1 percent for domestic drug companies.
The inclusion in the health care catalog has also encouraged many ophthalmologists and patients.
According to understand, for the domestic many ordinary patients, suitable for macular degeneration of ophthalmic drug price is not low, analysis of agency predicted, permeability resistance of VEGF eye ophthalmic injection patient population amounted to less than 10%. In the treatment group, there is also a certain degree of treatment of the patients in the course of treatment, which also means that the patient's compliance has a large space to improve. After the compaq was incorporated into the category, patients paid 70 to 80 percent lower. This brings hope to countless patients.
The market and academia have high hopes for innovative drugs represented by Mr Lang, because of the powerful market volume behind health care.
Analysis, according to the IMS company did a drug if all goes well into the national health insurance, use new drug protection and market opportunities, usually produces more than 30% during the first two years of growth, for a lot of innovative medicine, unable to enter medical insurance directory means the whole variety of losses in the long run.
"In many cases, innovative drugs tend to be patient and have high social significance." Executives at a listed pharmaceutical company in the west say that the entry of innovative drugs into health care is of great significance to the people's livelihood, to promoting industrial innovation, and to the self-development of pharmaceutical companies.
The air vents have been opened, and for the innovative drug companies represented by kanghong pharmaceutical, the bright future is full of imagination.
PgUp [1] [2] PgDn
|
